News & Events about Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) Director Richard S. Levy sold 22,489 shares of the businesss stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $293.15, for a total transaction of $6,592,650.35. Following ...
StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL Get Rating) from a sell rating to a hold rating in a research note released on Thursday morning. MDGL has been the topic of a number of other research reports. Evercore ISI upped their target price on Madrigal ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) SVP Brian Joseph Lynch sold 13,000 shares of the firms stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $282.92, for a total transaction of $3,677,960.00. The transaction was...
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) insider Remy Sukhija sold 30,000 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, December 23rd. The shares were sold at an average price of $274.14, for a total value of $8,224,200.00. The transaction was ...